文献速递妇科肿瘤

晚期卵巢癌患者参加早期临床试验的疗效相关临床因素

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
PubMed 文献 · Eur J Cancer · 2017-03-06

本文回顾性分析了1998年6月至2010年10月在皇家马斯登医院(Royal Marsden Hospital)药物开发部参加I期试验的200例晚期卵巢癌(AOC)患者,共281次分配。135例(68%)患者开始至少1项试验,43例(20%)达到完全/部分缓解(CR/PR)。与CR/PR相关的因素包括既往治疗线数少、铂敏感疾病、既往治疗达CR/PR、ECOG体能状态评分、转移部位少、白蛋白和血红蛋白水平较高、白细胞计数和基线CA125水平较低、胚系BRCA1/2突变及较好的RMH预后评分。

要点

  • 200例晚期卵巢癌患者中135例(68%)开始至少1项I期试验,43例(20%)达到CR/PR。
  • CR/PR率:PARP抑制剂组18/79(23%),抗血管生成组9/65(14%),化疗联合组14/43(33%)。
  • 达到CR/PR的患者平均生存期为32个月。

核心结论

  • 数据提示,晚期卵巢癌患者的I期试验转诊应考虑更早进行,尤其是在快速疾病进展出现之前,特别是在精准医学时代出现有前景的新药时。

研究设计与样本

  • 回顾性综述,纳入1998年6月至2010年10月在皇家马斯登医院药物开发部参加I期试验的200例晚期卵巢癌患者,共281次分配。

主要发现

  • 135例(68%)患者开始至少1项试验(平均1.4项,范围1-8),共216项分配试验;65例(32%)患者未开始,其中63例因快速进展性疾病恶化、2例因患者选择。
  • 开始试验的患者中43例(20%)达到RECIST完全/部分缓解(CR/PR),包括PARP抑制剂组18/79(23%)、抗血管生成组9/65(14%)、化疗联合组14/43(33%)。
  • 与CR/PR相关的因素包括:既往治疗线数较少、铂敏感疾病、既往治疗达CR/PR、ECOG体能状态评分、转移部位较少、白蛋白和血红蛋白水平较高、白细胞计数和基线CA125水平较低、胚系BRCA1/2突变及较好的RMH预后评分。
  • 达到CR/PR的患者平均生存期为32个月。
  • 大多数患者(134/200 [67%])在I期试验后接受了至少1线后续治疗。

关键数值与推荐

  • CR/PR率:PARP抑制剂组18/79(23%),抗血管生成组9/65(14%),化疗联合组14/43(33%)。
  • 达到CR/PR的患者平均生存期为32个月。

临床怎么用

  • 作者认为,晚期卵巢癌患者的I期试验转诊应考虑更早进行,尤其是在快速疾病进展出现之前,特别是在精准医学时代出现有前景的新药时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug development unit may represent a viable alternative; however, there is currently little evidence for patient outcomes in such patients. To address this, we undertook a retrospective review of patients with AOC allocated to phase I trials in the Drug Development Unit at Royal Marsden Hospital (RMH) between June 1998 and October 2010. A total of 200 AOC patients with progressive disease were allocated to ≥1 trial each, with a total of 281 allocations. Of these, 135 (68%) patients commenced ≥1 trial (mean 1.4 [1-8]), totaling 216 allocated trials; 65 (32%) patients did not start due to deterioration resulting from rapidly progressive disease (63 patients) or patient choice (2 patients). Response Evaluation Criteria in Solid Tumours (RECIST) complete/partial responses (CR/PR) were observed in 43 (20%) of those starting trials, including those on poly(ADP-ribose) polymerase (PARP) inhibitors (18/79 [23%]), antiangiogenics (9/65 [14%]) and chemotherapy combinations (14/43 [33%]). Factors associated with CR/PR included: fewer prior treatments, platinum-sensitive disease, CR/PR with prior therapy, (the United States-based) Eastern Cooperative Oncology Group (ECOG) performance status score, fewer metastatic sites, higher albumin and haemoglobin levels, lower white cell counts and baseline CA125 levels, germline BRCA1/2 mutations and better RMH Prognostic Score. Mean survival was 32° months for patients who achieved CR/PR. Treatments were generally well tolerated. Most patients with AOC (134/200 [67%]) received ≥1 subsequent line of therapy after phase I trials. Our data suggest that phase I trial referrals should be considered earlier in the AOC treatment pathway and before the onset of rapid disease progression particularly with the emergence of promising novel agents in the era of precision medicine.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. George A, Kristeleit R, Rafii S, et al. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur J Cancer. 2017. PMID: 28273485. doi:10.1016/j.ejca.2017.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。